The use of hyaluronic acid in the treatment of osteoarthritis of knee cartilage

• Autorzy: Kwasek B. , Bogdał D.

Warianty tytułu

PL

Zastosowanie kwasu hialuronowego w leczeniu choroby zwyrodnieniowej stawu kolanowego

• Języki publikacji: EN

Abstrakty

EN

The aim of this paper is to describe the possibilities of the therapeutic use of hyaluronic acid (HA) in the treatment of osteoarthritis of knee cartilage. This work provides an overview of the literature relating to the structure of hyaluronic acid, its properties and important functions of the human body. Moreover, the construction of the articular cartilage in the knee joint, including events leading to its degeneration, is presented. Viscosupplementation is a treatment for osteoarthritis involving several intra-articular injections of HA at specific time intervals. This treatment results in an increased lubricity, viscosity and elasticity of articular cartilage. Since HA is found naturally in the human body, viscosupplementation improves the biomechanical conditions of the joint whilst minimizing the side-effects of treatment. Hyaluronic acid occurs naturally in a linear form, but for many applications, chemical modifications are necessary. Thanks to this property, it remains in the body long enough to produce the desired therapeutic effect. Modification processes, in particular the cross-linking of HA, increase the mechanical properties of knee cartilage. HA is an example of a new kind of tissue engineering scaffold that is bioactive in both full-length and degraded forms. In turn, hydrogel scaffolds with interpenetrating polymeric network (IPN) gels can simulate the structure of the native extracellular matrix of cartilage tissue.

PL

Celem badań jest przedstawienie możliwości terapeutycznego zastosowania kwasu hialuronowego w leczeniu choroby zwyrodnieniowej chrząstki stawu kolanowego. Praca zawiera przegląd literatury dotyczący struktury kwasu hialuronowego, jego właściwości oraz ważnych funkcji jakie pełni w ludzkim organizmie, ponadto budowy chrząstki stawowej w stawie kolanowym oraz czynników prowadzących do jej degeneracji. Wiskosuplementacja jest metodą leczenia osteoporozy polegającą na dostawowych wstrzyknięciach tego biopolimeru w określonych odstępach czasu oraz kilkakrotnych powtórzeniach. Leczenie zwiększa lepkość oraz elastyczność chrząstki stawowej, która jest lepiej odżywiana. Wiskosuplementacja poprawia warunki biomechaniczne stawu, co więcej kwas hialuronowy występuje naturalnie w organizmie człowieka, w ten sposób pomaga zminimalizować skutki uboczne leczenia. W naturalnej postaci kwas hialuronowy występuje w postaci liniowej, ale w wielu zastosowaniach konieczna jest jego modyfikacja chemiczna. Dzięki tej właściwości pozostaje w organizmie na tyle długo, aby wywołać pożądany efekt terapeutyczny. Procesy modyfikacji, w szczególności sieciowanie kwasu hialuronowego zwiększa właściwości mechaniczne materiału. Badania potwierdzają, że hydrożelowe rusztowania z wzajemnie przenikającymi się sieciami polimerowymi (IPNs) mogą symulować strukturę natywną macierzy zewnątrzkomórkowej chrząstki.

Słowa kluczowe

EN

hyaluronic acid; knee cartilage; osteoarthritis; viscosupplementation; interpenetrating polymer network; IPNs; scaffolds

PL

kwas hialuronowy; chrząstka kolanowa; osteoporoza; wiskosuplementacja; IPNs; rusztowania

• Wydawca: Wydawnictwo Politechniki Krakowskiej im. Tadeusza Kościuszki
• Czasopismo: Czasopismo Techniczne. Chemia
• Rocznik: 2014
• Tom: R. 111, z. 1-Ch
• Strony: 57--68
• Opis fizyczny: Bibliogr. 63 poz., wz., wykr., il.

Twórcy

autor

Kwasek B.

• Chair of Biotechnology and Physical Chemistry, Faculty of Chemical Engineering and T echnology, Cracow University of T echnology

autor

Bogdał D.

• Chair of Biotechnology and Physical Chemistry, Faculty of Chemical Engineering and T echnology, Cracow University of T echnology

Bibliografia

• [1] Rügheimer L., Hyaluronian: A matrix component, Proc. AIP Conf. 1049, 2008, 126-132.
• [2] Czajkowska D., Milner-Krawczyk M., Kozanecka M., Kwas hialuronowy – charakterystyka, otrzymywanie i zastosowanie, Wydział Chemiczny, Instytut Technologii i Biotechnologii Środków Leczniczych, Politechnika Warszawska. Biotechnol. Ford Sci., 75(2), 2011, 55-70.
• [3] Volpi N., Schiller J., Stern R., Soltes L., Role, metabolism, chemical modifications and application of Hyaluronan, Volume 16, Number 14, May 2009, 1718-1745(28).
• [4] Levangie P.K., Norkin C.C., eds., Joint structure and function: a comprehensive analysis. 3rd ed. Philadelphia, FA Davis, 80 (8), 2005.
• [5] Ulrich-Vinther M., Maloney M.D., Schwarz E.M., Rosier R., Keefe R.J., Articular cartilage biology, J. Am. Acad. Orthop. Surg., 11, 2003, 421-430.
• [6] Marczyński W., Patologia chrząstki stawowej – dynamika zmian, zapobieganie, Wiadomości Lekarskie, LX, 2007, 1-2.
• [7] Kang R., Ghivizzani S.C., Muzzonigro T.S., Herndon J.H., Robbins P.D., Evans C.H., Orthopaedic applications of gene therapy: from concept to clinic, Clin. Orthop. Relat. Res., 375, 2000, 324-337.
• [8] Brief A.A., Mauer S.G., DiCesare P.E., Use of glucosamine and chondroitin sulfate in the management of osteoarthritis, J. Am. Acad. Orthop. Surg., 9, 2001, 71-78.
• [9] Górecki A. i wsp., Epidemiologia, stan profilaktyki, diagnostyki i leczenie chorób układu kostno-stawowego w Polsce, Dekada kości i stawów 2000–2010, Kraków 2000.
• [10] Brandt K.D., Block J.A., Michalski J.P., Moreland L.W., Caldwell J.R., Lavin P.T., Efficacy and safety of intra-arcikular sodium hyaluronate in knee osteoarthritis, ORTOVISC Study Group. Clin. Orthop. Relat. Res., 385, 2001, 130-43.
• [11] Bert J.M., Waddell D.D., Viscosupplementation with hylan g-f 20 in patients with osteoarthrosis of the knee, Ther Adv Musculoskelet Dis., 2(3), Jun 2010, 127-32.
• [12] Sanofiaventis Hyalgan [prescribing information], Sanofiaventis US LLC: Bridgewater, NJ, 2007.
• [13] Seikagaku Supartz [product information], Seikagaku, Tokio 2007.
• [14] Ferring Pharmaceuticals Euflexxa [prescribing information], Ferring Pharmaceuticals, Saint-Prex, Switzerland, 2006.
• [15] Genzyme Biosurgery., Synvisc (hylan G-F 20) [product information], Genzyme Biosurgery: Cambridge, MA, 2006.
• [16] Anika Therapeutics., Orthovisc (sodium hyaluronate) [product information], Anika Therapeutics, Woburn, MA, 2005.
• [17] Scientific Group WHO, The burden of musculoskeletal conditions at the start of the new millennium, World Health Organ. Tech. Rep. Ser., 919, 2003, I-IX, 1-218.
• [18] Raman R., Dutta A., Day N., Sharma H.K., Shaw C.J., Johnson G.V., Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee–a prospective randomized clinical trial, Knee, 15, 2008, 318-324.
• [19] Kirchner M., Marshall D., A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee, Osteoarthritis 14, Cartilage 2006, 154-162.
• [20] Waddell D., Bricker D., Clinical experience with the effectiveness and tolerability of hylan G-F 20 in 1047 patients with osteoarthritis of the knee, J Knee Surg., 19, 2006, 19-27.
• [21] Clarke S., Lock V., Duddy J., Sharif M., Newman J.H., Kirwan J.R., Intra-articular hylan G-F 20 (Synvisc) in the management of patel-lofemoral osteoarthritis of the knee (POAK), Knee, 12, 2005, 57-62.
• [22] Kemper F., Gebhardt D., Meng T., Murray C., Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice, Curr. Med. Res. Opin., 21, 2005, 1261-1269.
• [23] Caborn O., Rush J., Lanzer W., Parenti O., Murray C.A., Randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee, J. Rheumatol. 31, 2004, 333-343.
• [24] Kahan A., Lieu P., Salin L., Prospective randomized study comparing the medicoeconomic benefits of hylan G-F 20 vs. conventional treatment in knee osteoarthritis, Joint Bone Spine, 70, 2003, 276-281.
• [25] Neustadt D., Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee, Clin. Exp. Rheumatol., 21, 2003, 307-311.
• [26] Raynaud J., Torrance G., Band P.A., Prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2), Clinical results. Osteoarthritis Cartilage, 10, 2002, 506-517.
• [27] Evanich J., Evanich C., Wright M., Rydlewicz J., Efficacy of intraarticular hyaluronic acid injections in knee osteoarthritis, Clin. Orthop. Relat. Res., 390, 2001, 173-181.
• [28] Huskisson E., Donnelly S., Hyaluronic acid in the treatment of osteoarthritis of the knee, Rheumatology, 38, 1999, 602-607.
• [29] Wobig M., Bach G., Beks P., Dickhut A., Runzheimer J., Schwieger G., Vetter G., Balazs E., The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: A comparison of Hylan G-F 20 and a lower-molecular-weight hyaluronan, Clinical Therapeutics, Volume 21, Issue 9, September 1999, 1549-1562.
• [30] Wobig M., Beks P., Dickhut A., Maier R., Vetter G., Open-label multicenter trial of the safety and efficacy of viscosupplementation with hylan G-F 20 (Synvisc) in primary osteoarthritis of the knee, J. Clin. Rheumatol., 5, 1999, S24-S31
• [31] Altman R., Moskowitz R., Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial, Hyalgan Study Group, J. Rheumatol., 25, 1998, 2203-2212.
• [32] Wobig M., Dickhut A., Maier R., Veller G., Viscosupplementation with hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee, Clin. Ther., 20, 1998, 410-423.
• [33] Lussier A., Cividino A., McFarlane C., Olszynski W., Potashner W., De Medicis R., Viscosupplementation with hylan for the treatment of osteoarthritis: Findings from clinical practice in Canada, J. Rheumatol., 23, 1996, 1579-1585.
• [34] Carrabba M., Paresce E., Angelini M., Re K., Torchiana E., Perbellini A., The safety and efficiency of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion, Eur. J. Rheumatol. Inflamm., 15, 1995, 25-31.
• [35] Scale D., Wobig M., Wolpert W., Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study, Curr. Ther. Res., 55, 1994, 220-232.
• [36] Dougados M., Nguyen M., Listrat V., Amor B., High molecular weight sodium hyaluronate (Hyalectin) in osteoarthritis of the knee: a 1 year placebo-controlled trial, Osteoarthritis Cartilage 1, 1993, 97-103.
• [37] Grecomoro G., Martorana D., Di Marco C., Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo, Pharmatherapeutica, 5, 1987, 137-141.
• [38] Moskowitz W.R., Hyaluronic Acid Supplementation, Current Reumatology 2000, Reports, Volume 2, Issue 6, 466-471.
• [39] Conrozier T., Mathieu P., Schott A.M., Laurent I., Hajri T., Crozes P., Grand P., Laurent H., Marchand F., Meignan F., Noel E., Rozand Y., Savoye J.F., Vignon E., Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis, Joint Bone Spine, 70(2), 2003, 128-133.
• [40] Brandt K.D., Block J.A., Michalski J.P., Moreland L.W., Caldwell J.R., Lavin P.T., Efficacy and safety of intra-arcikular sodium hyaluronate in knee osteoarthritis, ORTOVISC Study Group, Clin. Orthop. Relat. Res., 385, 2001, 130-43.
• [41] Navarro-Sarabia F., Coronel P., Collantes E., A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis, Annals of the rheumatic diseases, 08/2011, 70(11), 2011, 1957-1962.
• [42] Lester D.K., Hang K., Gait Analysis of Knee Arthritis Treated With Hyaluronic, Acid the Journal of Arthroplasty, 25(8), 2010.
• [43] Keith M.P., Updates on Intra-Articular Hyaluronic Acid Therapy for Knee Osteoarthritis, Am J. Orthop., 41(4), 2012, E61-E63.
• [44] Bannuru R.R, Natov N.S., Dasi U.R., Schmidt C.H. McAlindon, Terapeutic trajectory following intra-articular hyaluronic acid injection In knee osteoarthritis – meta-analysis, Osteoarthritis and Cartilage, 2011, 19611-619.
• [45] Wang C., Lin J., Chang C., Lin Y., Hou S., Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials, J Bone Joint Surg. Am 86A, 2004, 538-545.
• [46] Marshall O., Johnell O., Wedel H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, 312, 1996, 1254-1259.
• [47] Chen Y., Peng O., Sun C., Wang W., Li J., Zhang W., Clinical study on sodium hyaluronate intra-articular injection in treatment of degenerative osteoarthritis of knee, Zhongguo Xiu Follow up Chong lian Wai Ke Za Zhi, 16, 2002, 19-20.
• [48] Hempfling H., Intra-articular hyaluronic acid after knee arthroscopy: a two- year study, Knee Surgery, Sports Traumatology, Arthroscopy, 15, 5, 2007, 537-546.
• [49] Zietz P., Selesnick H., The use of hylan G-F 20 after knee arthroscopy in an active patient population with knee osteoarthritis, Arthroscopy, 24, 2008, 416-422.
• [50] Huskin J., Vandekerckhove B., Delince P., Multicentre, prospective, open study to evaluate the safety and efficacy of hylan G-F 20 in knee osteoarthritis subjects presenting with pain following arthroscopic meniscectomy, Knee Surg. Sports Traumatol. Arthrosc., 16, 2005, 747-752, analysis. 3rd ed. Philadelphia: FA Davis 80:8.
• [51] Lo G., LaValley M., McAlindon T., Felson D., Intra-articular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis, JAMA, 290, 2004, 3115-3121.
• [52] Collins M.N., Birkinshaw C., Hyaluronic Acid Based Scaffolds for Tissue Engineering-a Review. Carbohydrate polymers, 92.2, 2013, 1262-79, Web. 23.
• [53] Bergman K., Hilborn J., Bowden T., Hyaluronic Acid Crosslinking Chemistry, Journal Article 2005, 7-8.
• [54] Guo Y., Yuan T., Xiao Z., Tang P., Xiao Y., Fan Y. & Zhang X., Hydrogels of collagen/chondroitin sulfate/hyaluronan interpenetrating polymer network for cartilage tissue engineering. Journal of materials science, Materials in medicine, 23(9), 2012, 2267-79.
• [55] Tan H., Chu CR, Payne K.A., Marra K.G., Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering, Biomaterials, 30(13), 2009, 2499-506.
• [56] Park H., Choi B., Hu J., Lee M., Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering, Acta Biomater, 9(1), 2013, 4779-4786.
• [57] Lisignoli G., Toneguzzi S., Zini N., Piacentini A., Cristino S., Tschon M et al., Hyaluronan-based biomaterial (Hyaff-11) as scaffold to support mineralization of bone marrow stromal cells, La Chirurgia Degli Organi de Movimento, 88(4), 2003, 363-367.
• [58] Lisignoli G., Cristino S., Piacentini A., Toneguzzi S., Grassi F., Cavallo C., Zini N., Solimando L., Maraldi M.N., Facchini A., Cellular and molecular events during chondrogenesis of human mesenchymal stromal cells grown in a three-dimensional hyaluronan based scaffold, Biomaterials October 2005, Volume 26, Issue 28, 5677-5686.
• [59] Lepidi S., Grego S., Vindigni V., Zavan B., Tonello C., Deriu G.P., Abatangelo G., Cortivo R., Hyaluronan Biodegradable Scaffold for Small-caliber Artery Grafting: Preliminary Results in an Animal Model, 417, 2006, 411-417.
• [60] Radice M., Brun P., Cortivo R., Scapinelli R., Battaliard C., Abatangelo G., Hyaluronan-based biopolymers as delivery vehicles for bone-marrow-derived mesenchymal progenitors, Journal of biomedical materials research, 50(2), 2000, 101-9 (retrieved from: http://www.ncbi.nlm.nih.gov/pubmed/10679672).
• [61] Kim M., Garrity S., Erickson I.E., Huang A.H., Burdick J.A., Mauck R.L., Optimization of Macromer Density in Human MSC-Laden Hyaluronic Acid (HA) Hydrogels, 2012, 211-212.
• [62] Allison D.D., Grande-Allen K.J., Review. Hyaluronan: A Powerful Tissue Engineering Tool, Tissue Engineering, Vol. 12, No. 8, August 2006, 2131-2140.
• [63] Chung C.W., Kang J.Y., Yoon I.S., Hwang H.D., Balakrishnan P., Cho H.J., Chung K.D., Kang D.H., Kim D.D., Interpenetrating polymer network (IPN) scaffolds of sodium hyaluronate and sodium alginate for chondrocyte culture, Colloids Surf. B Biointerfaces., 1, 88(2), Dec 2011, 711-6.